Alpha Teknova, Inc.
TKNO
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $371.0M
$6.92
▼ -4.42%
P/E
-22.32
Mkt Cap
$371.0M
52-Wk Range
$1.91–$7.84
52-Week Range
$1.91 - $7.84
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 59.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Regulatory Certifications and Quality Standards - FDA compliance and stringent manufacturing protocols create high barriers to entry
- Established Customer Relationships - Long-standing partnerships with major pharmaceutical, biotech, and research institutions
- Specialized Product Portfolio - Focused expertise in critical reagents with limited direct competitors in specific niches
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Stable outlook
Expanding Biopharmaceutical R&D - Increased drug development pipelines and vaccine research globally
Value
Deep value opportunity - significant discount to Large Cap Pharma peers
Momentum
Hot
+48.8% over 3m
Quality
Stable
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying TKNO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 5, 2026
Reported EPS of -$0.06 vs -$0.08 consensus (+28.8% surprise). Revenue of $12.2M vs $11.0M expected (+11.3%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+28.8%
Revenue trend · last 8Q
—
+18%
+5%
+7%
+9%
+8%
+13%
+18%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$9.6M
$9.3M
$9.8M
$10.3M
$10.5M
$10.0M
$11.1M
$12.2M
Margins · last 8Q
Gross
42.5%
Operating
-23.7%
Profit
-26.0%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: BTIG · Aug 11, 2026
vs Industry
How TKNO stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related